L
Lumen Bioscience
Discovers, develops and manufactures biologic drugs and vaccine candidates for several prevalent, worldwide diseases
About Lumen Bioscience
Lumen Bio is a biotechnology startup that is revolutionizing the development and distribution of biologic drugs. Biologic drugs are products that are produced from living organisms or contain components of living organisms. These drugs have immense potential in treating various diseases but have been limited by the lack of scalable technology. Lumen Bio is addressing this gap by leveraging its patented technology to develop these drugs faster, at a lower cost, and with less risk than traditional methods.
The company operates in the biopharmaceutical market, serving a broad range of clients including hospitals, healthcare providers, and patients suffering from diseases such as Inflammatory Bowel Disease (IBD) and metabolic diseases. These are conditions that have been largely neglected by the healthcare industry due to the high costs associated with their treatment.
Lumen Bio's business model is centered around the development and commercialization of biologic drugs. The company makes money by selling these drugs to healthcare providers and hospitals. By reducing the cost and time of development, Lumen Bio is able to offer these drugs at a more affordable price, thereby increasing access for patients who need them.
In addition, Lumen Bio is also addressing other health issues such as gastrointestinal symptoms, which affect a significant number of patients, and diseases that are a leading cause of death worldwide. The company is also developing therapies for mild-to-moderate Crohn's disease and is working to protect travelers and US servicemembers from health risks.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Seattle, United States
- Employees
- 112
- Open positions
- None listed
- Dealroom signal
- 87.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Algae, Synthetic Biology, Spinout, Alternative Protein, Biotech and Pharma, Blue Economy, Blue Biotechnology, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2025 | $30M | $252M | Matt Horner · WestRiver Group · Jerry Yang · Jeff Raikes | ↗ |
| LATE VCOther financing | Sep 2023 | $17M | $252M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Lumen Bioscience is 5.4K monthly website visits, up 20% over the last three months. Lumen Bioscience's team grew 8.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
CARB-X
MTEC
US Department of War
Series A5 investors entered at this stage
Bioeconomy Capital
WestRiver Group
Columbia Pacific Advisors
Jim Roberts
Brian Finrow
Series B and later7 investors entered at this stage
Matt Horner
Jerry Yang
Jeff Raikes
Adebayo O. Ogunlesi
Bill & Melinda Gates Foundation
David Siegel
Jim Kavanaugh
Other known investors1 additional known investor
Fred Hutchinson Cancer Research Center
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lumen Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lumen Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







